5-羟色胺与帕金森病非运动症状研究进展

doi:10.3969/j.issn.1672-6731.2024.06.013

中国现代神经疾病杂志 ›› 2024, Vol. 24 ›› Issue (6): 497-501. doi: 10.3969/j.issn.1672-6731.2024.06.013

2 5-羟色胺与帕金森病非运动症状研究进展

史若琳¹, 高秀洁², 崔家宁¹, 邵妍³, 谢璐霜⁴, 刘毅¹^,*()

1. 116033 大连理工大学附属中心医院神经内科
2. 116033 大连医科大学放射影像学院2022级
3. 118000 辽宁省丹东市中心医院神经内科
4. 610075 成都中医药大学基础医学院

收稿日期:2023-11-09 出版日期:2024-06-25 发布日期:2024-07-05
通讯作者: 刘毅
基金资助:
国家自然科学基金资助项目(82174511); 辽宁省“兴辽英才计划”项目(XLYC1807083); 辽宁省大连市科技创新惠民计划项目(2021JJ13SN64); 辽宁省大连市生命健康领域指导计划项目(2022ZXYG31); 辽宁省大连市中心医院“登峰计划”项目(2023ZZ010)

Advance on association between 5-hydroxytryptamine and non-motor symptoms in Parkinson's disease

Ruo-lin SHI¹, Xiu-jie GAO², Jia-ning CUI¹, Yan SHAO³, Lu-shuang XIE⁴, Yi LIU¹^,*()

1. Department of Neurology, Central Hospital of Dalian University of Technology, Dalian 116033, Liaoning, China
2. Grade 2022, Discipline of Radiology, Dalian Medical University, Dalian 116033, Liaoning, China
3. Department of Neurology, Dandong Central Hospital, Dandong 118000, Liaoning, China
4. College of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, Sichuan, China

Received:2023-11-09 Online:2024-06-25 Published:2024-07-05
Contact: Yi LIU
Supported by:
the National Natural Science Foundation of China(82174511); Liaoning "Xingliao Talents Plan" Project(XLYC1807083); Dalian Science and Technology Innovation Benefits the People Plan in Liaoning(2021JJ13SN64); Dalian Life Health Area Guidence Program in Liaoning(2022ZXYG31); Science and Technology Program of Dalian Central Hospital "Peak Climbing Program" in Liaoning(2023ZZ010)

摘要/Abstract

摘要：

帕金森病是临床常见的神经系统变性疾病，通常伴有胃肠功能障碍、嗅觉减退、睡眠障碍、抑郁、疼痛和幻觉等非运动症状，严重降低患者生活质量。帕金森病患者存在5-羟色胺能神经元退行性变等非多巴胺能系统弥漫性病理改变，且5-羟色胺在情绪、认知功能、疼痛等多种神经功能调节方面发挥重要作用，与帕金森病非运动症状密切相关。本文综述5-羟色胺与帕金森病非运动症状之间的相关性及其研究进展，以明确帕金森病非运动症状的发病机制，为实现疾病的早期诊断与精准治疗提供理论基础。

关键词: 帕金森病, 血清素, 综述

Abstract:

Parkinson's disease (PD) is a common neurodegenerative disease in clinical practice. Patients with PD are usually accompanied by non-motor symptoms (NMS) such as gastrointestinal dysfunction, hyposmia, sleep disorders, depression, pain and hallucinations, which seriously reduce the quality of life. Recent studies have found that PD patients were accompanied by diffuse pathological changes in non-dopaminergic system such as progressive degeneration of 5 -hydroxytryptamine (5-HT) ergic neurons, and 5-HT plays an important role in the regulation of emotion, cognitive function, pain and other neural functions, and is closely related to non-motor symptoms of PD. This article reviews the correlation between 5-HT and non-motor symptoms of PD and its research progress, in order to further clarify the pathogenesis of non-motor symptoms of PD and provide a theoretical basis for the treatment of PD.

Key words: Parkinson disease, Serotonin, Review

史若琳, 高秀洁, 崔家宁, 邵妍, 谢璐霜, 刘毅. 5-羟色胺与帕金森病非运动症状研究进展[J]. 中国现代神经疾病杂志, 2024, 24(6): 497-501.

Ruo-lin SHI, Xiu-jie GAO, Jia-ning CUI, Yan SHAO, Lu-shuang XIE, Yi LIU. Advance on association between 5-hydroxytryptamine and non-motor symptoms in Parkinson's disease[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2024, 24(6): 497-501.

http://journal11.magtechjournal.com/cjcnn/CN/Y2024/V24/I6/497

参考文献 45

1	Leite Silva ABR, Gonçalves de Oliveira RW, Diógenes GP, de Castro Aguiar MF, Sallem CC, Lima MPP, de Albuquerque Filho LB, Peixoto de Medeiros SD, Penido de Mendonça LL, de Santiago Filho PC, Nones DP, da Silva Cardoso PMM, Ribas MZ, Galvão SL, Gomes GF, Bezerra de Menezes AR, Dos Santos NL, Mororó VM, Duarte FS, Dos Santos JCC. Premotor, nonmotor and motor symptoms of Parkinson's disease: a new clinical state of the art. Ageing Res Rev, 2023, 84: 101834. doi: 10.1016/j.arr.2022.101834
2	Chen ZJ, Ma J, Tang N, Yang YD, He QY, Zhou JH. Disease burden trend analysis and prediction of Parkinson's disease in China. Zhongguo Man Xing Bing Yu Fang Yu Kong Zhi, 2022, 30: 649- 654. URL
	陈芝君, 马建, 唐娜, 阳益德, 贺权源, 周军华. 中国帕金森病疾病负担变化趋势分析及预测. 中国慢性病预防与控制, 2022, 30: 649- 654. URL
3	Liu W, Zhao H, Xia ZY, Liu HY, Lu ZY. Pathological evolution research progress of Parkinson's disease. Shen Jing Sun Shang Yu Gong Neng Chong Jian, 2022, 17: 148- 151. URL
	刘旺, 赵虹, 夏兆云, 刘慧瑛, 陆征宇. 帕金森病相关病理演变研究进展. 神经损伤与功能重建, 2022, 17: 148- 151. URL
4	Qi X, Li JH, Zhu YF, Yu L, Wang P. Abnormal modification of alpha-synuclein and its mechanism in Parkinson's disease. Zhongguo Zu Zhi Gong Cheng Yan Jiu, 2024, 28: 1301- 1306. doi: 10.12307/2024.228
	齐雪, 李家慧, 朱远峰, 禹璐, 王鹏. α-突触核蛋白的异常修饰及在帕金森病中的作用机制. 中国组织工程研究, 2024, 28: 1301- 1306. doi: 10.12307/2024.228
5	Pinna A, Parekh P, Morelli M. Serotonin 5-HT_1A receptors and their interactions with adenosine A_2A receptors in Parkinson's disease and dyskinesia. Neuropharmacology, 2023, 226: 109411. doi: 10.1016/j.neuropharm.2023.109411
6	La XM, Guo Y, Liu J, Li XY, Zhang L. Advances in the role of 5-HT neurotransmitter system in psychiatric symptoms and cognitive impairment associated with Parkinson's disease. Sheng Li Ke Xue Jin Zhan, 2023, 54: 177- 184. doi: 10.3969/j.issn.0559-7765.2023.03.003
	喇雪梅, 郭媛, 刘健, 李小颖, 张莉. 5-HT递质系统调节帕金森病精神症状和认知障碍的研究进展. 生理科学进展, 2023, 54: 177- 184. doi: 10.3969/j.issn.0559-7765.2023.03.003
7	Li XX, Lu SF, Zhu BM, Jing XY, Fu SP. Research progress of 5-HT and gut microbiota and its role in gut-brain related diseases. Zhongguo Kang Fu Yi Xue Za Zhi, 2019, 34: 116- 119. doi: 10.3969/j.issn.1001-1242.2019.01.026
	李潇潇, 卢圣锋, 朱冰梅, 景欣悦, 傅淑平. 5-HT与肠道菌群及其在肠-脑相关疾病中的作用研究进展. 中国康复医学杂志, 2019, 34: 116- 119. doi: 10.3969/j.issn.1001-1242.2019.01.026
8	Li XL, Zhang QD. Characteristics of gastrointestinal dysfunction and risk factors in patients with Parkinson's disease. Zhonghua Xiao Hua Bing Yu Ying Xiang Za Zhi (Dian Zi Ban), 2023, 13: 145- 149. doi: 10.3877/cma.j.issn.2095-2015.2023.03.004
	李玺琳, 章邱东. 帕金森病患者胃肠功能障碍特点及其风险因素分析. 中华消化病与影像杂志(电子版), 2023, 13: 145- 149. doi: 10.3877/cma.j.issn.2095-2015.2023.03.004
9	Guzel T, Mirowska-Guzel D. The role of serotonin neurotransmission in gastrointestinal tract and pharmacotherapy. Molecules, 2022, 27: 1680. doi: 10.3390/molecules27051680
10	Qin ZW, Wang S, Bai Y, Li Y, Qiao GQ, Wei B, Fu Y. Effect of acupuncture on GDNF content and gastrointestinal physiological indexes in different parts of PD gastrointestinal dysfunction rats. Xian Dai Sheng Wu Yi Xue Jin Zhan, 2022, 22: 615- 620. URL
	秦正巍, 王顺, 白妍, 李元, 乔国强, 韦波, 付艺. 针刺对PD胃肠功能障碍大鼠不同部位GDNF含量及胃肠生理指标的影响. 现代生物医学进展, 2022, 22: 615- 620. URL
11	Zhu XQ, Liu GY, Zeng QY, Qin DY, Zhou XQ, Zhang Y, Zhang DK. Research progress in 5-hydroxytryptamine and irritable bowel syndrome. Yi Xue Zong Shu, 2022, 28: 2482- 2486. doi: 10.3969/j.issn.1006-2084.2022.12.034
	朱小琴, 刘光耀, 曾琪璎, 覃冬媛, 周雪琪, 张宇, 张德奎. 5-羟色胺与肠易激综合征的研究进展. 医学综述, 2022, 28: 2482- 2486. doi: 10.3969/j.issn.1006-2084.2022.12.034
12	Shi Y, Qiao CM, Zhou Y, Wu J, Cui C, Hong H, Jia XB, Huang SB, Yao L, Zhao WJ, Shen YQ. Protective effects of prucalopride in MPTP-induced Parkinson's disease mice: neurochemistry, motor function and gut barrier. Biochem Biophys Res Commun, 2021, 556: 16- 22. doi: 10.1016/j.bbrc.2021.03.109
13	Zhang X, Li Y, Liu C, Fan R, Wang P, Zheng L, Hong F, Feng X, Zhang Y, Li L, Zhu J. Alteration of enteric monoamines with monoamine receptors and colonic dysmotility in 6-hydroxydopamine-induced Parkinson's disease rats. Transl Res, 2015, 166: 152- 162. doi: 10.1016/j.trsl.2015.02.003
14	Koza J, Liebert A, Hołyńska-Iwan I, Piskorska P. Reduced sodium absorption in the colon under serotonin is a potential factor aggravating secretory diarrshea. Adv Clin Exp Med, 2023, 32: 481- 488.
15	Shi Y. Effects of 5-HT4 receptor antagonists on neuropathology in mice with Parkinson's disease through the gut-brain axis[D]. Wuxi: Jiangnan University, 2021.
	石芸. 5-HT4受体拮抗剂通过肠-脑轴加剧帕金森病小鼠神经病理的作用研究[D]. 无锡: 江南大学, 2021.
16	Manolakis AC, Broers C, Geysen H, Goelen N, Van Houtte B, Rommel N, Vanuytsel T, Tack J, Pauwels A. Effect of citalopram on esophageal motility in healthy subjects: implications for reflux episodes, dysphagia, and globus. Neurogastroenterol Motil, 2019, 31: e13632. doi: 10.1111/nmo.13632
17	Li L, Wang F, Lu ZZ, Zhang LF. The use of Ofactory Test of Parkinson's Disease (KinPamor) in evaluation of olfactory function in Parkinson's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2022, 22: 163- 167. doi: 10.3969/j.issn.1672-6731.2022.03.007
	李凌, 王峰, 卢镇泽, 张丽芳. 帕金森病嗅觉障碍辅助诊断卡对帕金森病患者嗅觉功能的评估作用. 中国现代神经疾病杂志, 2022, 22: 163- 167. doi: 10.3969/j.issn.1672-6731.2022.03.007
18	Wu QZ, Wang Q. Research progress on the correlation between hyposmia and non-motor symptoms in Parkinson's disease. Zhong Feng Yu Shen Jing Ji Bing Za Zhi, 2022, 39: 1052- 1056. URL
	吴巧珍, 王强. 帕金森病嗅觉减退与非运动症状的相关性研究进展. 中风与神经疾病杂志, 2022, 39: 1052- 1056. URL
19	Ren P, Chen YL, Zhang XW. Olfactory disorder in Parkinson's disease. Ji Chu Yi Xue Yu Lin Chuang, 2023, 43: 994- 997. URL
	任鹏, 陈雅丽, 张娴文. 帕金森病嗅觉障碍的研究进展. 基础医学与临床, 2023, 43: 994- 997. URL
20	Morais LH, Hara DB, Bicca MA, Poli A, Takahashi RN. Early signs of colonic inflammation, intestinal dysfunction, and olfactory impairments in the rotenone-induced mouse model of Parkinson's disease. Behav Pharmacol, 2018, 29(2 and 3-Spec Issue): 199- 210.
21	Sardar D, Cheng YT, Woo J, Choi DJ, Lee ZF, Kwon W, Chen HC, Lozzi B, Cervantes A, Rajendran K, Huang TW, Jain A, Arenkiel BR, Maze I, Deneen B. Induction of astrocytic Slc22a3 regulates sensory processing through histone serotonylation. Science, 2023, 380: eade0027. doi: 10.1126/science.ade0027
22	Yu LY, Peng L, Luo T, Huang CC, Wang ZX. Relationship study between sleep disorders and EEG activity, neuropsychological indicators and health-related quality of life in patients with Parkinson's disease. Xian Dai Sheng Wu Yi Xue Jin Zhan, 2022, 22: 3863- 3867. URL
	于利雅, 彭蕾, 罗婷, 黄陈程, 王兆霞. 帕金森病患者睡眠障碍与脑电图活动、神经心理学指标和健康相关生活质量的关系研究. 现代生物医学进展, 2022, 22: 3863- 3867. URL
23	Samizadeh MA, Fallah H, Toomarisahzabi M, Rezaei F, Rahimi-Danesh M, Akhondzadeh S, Vaseghi S. Parkinson's disease: a narrative review on potential molecular mechanisms of sleep disturbances, REM behavior disorder, and melatonin. Brain Sci, 2023, 13: 914. doi: 10.3390/brainsci13060914
24	Wang J, Sun J, Gao L, Zhang D, Chen L, Wu T. Common and unique dysconnectivity profiles of dorsal and median raphe in Parkinson's disease. Hum Brain Mapp, 2023, 44: 1070- 1078. doi: 10.1002/hbm.26139
25	Meloni M, Figorilli M, Carta M, Tamburrino L, Cannas A, Sanna F, Defazio G, Puligheddu M. Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease. Sleep Breath, 2022, 26: 1023- 1031. doi: 10.1007/s11325-021-02417-w
26	Stefani A, Santamaria J, Iranzo A, Hackner H, Schenck CH, Högl B. Nelotanserin as symptomatic treatment for rapid eye movement sleep behavior disorder: a double-blind randomized study using video analysis in patients with dementia with Lewy bodies or Parkinson's disease dementia. Sleep Med, 2021, 81: 180- 187. doi: 10.1016/j.sleep.2021.02.038
27	Li X, Ren N, Wang M, Chen XJ, Chen L. Correlation between the time from rapid eye movement sleep behavior disorder to disease onset and clinical characteristics in Parkinson's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2022, 22: 168- 172. doi: 10.3969/j.issn.1672-6731.2022.03.008
	李欣, 任宁, 王敏, 陈学姣, 陈蕾. 快速眼动睡眠期行为障碍发病至运动症状出现时间间隔与帕金森病临床特征之相关研究. 中国现代神经疾病杂志, 2022, 22: 168- 172. doi: 10.3969/j.issn.1672-6731.2022.03.008
28	Laux G. Parkinson and depression: review and outlook. J Neural Transm (Vienna), 2022, 129: 601- 608. doi: 10.1007/s00702-021-02456-3
29	Erritzoe D, Godlewska BR, Rizzo G, Searle GE, Agnorelli C, Lewis Y, Ashok AH, Colasanti A, Boura I, Farrell C, Parfitt H, Howes O, Passchier J, Gunn RN, Politis M, Nutt DJ, Cowen PJ, Knudsen GM, Rabiner EA. Brain serotonin release is reduced in patients with depression: a[¹¹C]Cimbi-36 positron emission tomography study with a D-amphetamine challenge. Biol Psychiatry, 2023, 93: 1089- 1098. doi: 10.1016/j.biopsych.2022.10.012
30	Miquel-Rio L, Sarriés-Serrano U, Pavia-Collado R, Meana JJ, Bortolozzi A. The role of α-synuclein in the regulation of serotonin system: physiological and pathological features. Biomedicines, 2023, 11: 541. doi: 10.3390/biomedicines11020541
31	Huang R, Li XH, Chen WW. Effects of rTMS combined with paroxetine on cognitive status, depression symptoms, serum 5-HT and IL-1β in PD-D patients. Guo Ji Jing Shen Bing Xue Za Zhi, 2023, 50: 466- 468. URL
	黄荣, 李晓晖, 陈文武. 重复经颅磁刺激联合帕罗西汀对帕金森合并抑郁患者认知、情绪及血清5-HT、IL-1β水平的影响. 国际精神病学杂志, 2023, 50: 466- 468. URL
32	Wu CJ. Clinical effect of escitalopram in the treatment of Parkinson's disease with depression. Lin Chuang He Li Yong Yao Za Zhi, 2021, 14: 62- 64. URL
	吴长江. 艾司西酞普兰治疗帕金森合并抑郁患者的临床效果. 临床合理用药杂志, 2021, 14: 62- 64. URL
33	Miquel-Rio L, Alarcón-Arís D, Torres-López M, Cóppola-Segovia V, Pavia-Collado R, Paz V, Ruiz-Bronchal E, Campa L, Casal C, Montefeltro A, Vila M, Artigas F, Revilla R, Bortolozzi A. Human α-synuclein overexpression in mouse serotonin neurons triggers a depressive-like phenotype: rescue by oligonucleotide therapy. Transl Psychiatry, 2022, 12: 79. doi: 10.1038/s41398-022-01842-z
34	Tang GY, Wang RJ, Guo Y, Liu J. 5-HT_1B receptor-AC-PKA signal pathway in the lateral habenula is involved in the regulation of depressive-like behaviors in 6-hydroxydopamine-induced Parkinson's rats. Neurol Res, 2023, 45: 127- 137. doi: 10.1080/01616412.2022.2124797
35	Gu SM, Yu E, Kim YE, Yoon SS, Lee D, Hong JT, Yun J. Peroxiredoxin 6 overexpression induces anxiolytic and depression-like behaviors by regulating the serotonergic pathway in mice. Biomol Ther (Seoul), 2022, 30: 334- 339. doi: 10.4062/biomolther.2021.169
36	Angelopoulou E, Bougea A, Paudel YN, Georgakopoulou VE, Papageorgiou SG, Piperi C. Genetic insights into the molecular pathophysiology of depression in Parkinson's disease. Medicina (Kaunas), 2023, 59: 1138. doi: 10.3390/medicina59061138
37	Li C, Jia J, Liu XY, Tian SL. Research progress of pain rehabilitation in Parkinson's disease. Zhongguo Yi Kan, 2023, 58: 123- 127. doi: 10.3969/j.issn.1008-1070.2023.02.003
	李冲, 贾杰, 刘向云, 田石榴. 帕金森病疼痛的康复研究进展. 中国医刊, 2023, 58: 123- 127. doi: 10.3969/j.issn.1008-1070.2023.02.003
38	Campos ACP, Berzuino MB, Hernandes MS, Fonoff ET, Pagano RL. Monoaminergic regulation of nociceptive circuitry in a Parkinson's disease rat model. Exp Neurol, 2019, 318: 12- 21. doi: 10.1016/j.expneurol.2019.04.015
39	Wang CT, Mao CJ, Zhang XQ, Zhang CY, Lv DJ, Yang YP, Xia KL, Liu JY, Wang F, Hu LF, Xu GY, Liu CF. Attenuation of hyperalgesia responses via the modulation of 5-hydroxytryptamine signalings in the rostral ventromedial medulla and spinal cord in a 6-hydroxydopamine-induced rat model of Parkinson's disease. Mol Pain, 2017, 13: 1744806917691525.
40	Li CJ, Zhang LG, Liu LB, An MQ, Dong LG, Gu HY, Dai YP, Wang F, Mao CJ, Liu CF. Inhibition of spinal 5-HT3 receptor and spinal dorsal horn neuronal excitability alleviates hyperalgesia in a rat model of Parkinson's disease. Mol Neurobiol, 2022, 59: 7253- 7264. doi: 10.1007/s12035-022-03034-8
41	Diez-Cirarda M, Cabrera-Zubizarreta A, Murueta-Goyena A, Strafella AP, Del Pino R, Acera M, Lucas-Jiménez O, Ibarretxe-Bilbao N, Tijero B, Gómez-Esteban JC, Gabilondo I. Multimodal visual system analysis as a biomarker of visual hallucinations in Parkinson's disease. J Neurol, 2023, 270: 519- 529. doi: 10.1007/s00415-022-11427-x
42	Bozymski KM, Lowe DK, Pasternak KM, Gatesman TL, Crouse EL. Pimavanserin: a novel antipsychotic for Parkinson's disease psychosis. Ann Pharmacother, 2017, 51: 479- 487. doi: 10.1177/1060028017693029
43	Tripathi A, Nasrallah HA, Pillai A. Pimavanserin treatment increases plasma brain-derived neurotrophic factor levels in rats. Front Neurosci, 2023, 17: 1237726. doi: 10.3389/fnins.2023.1237726
44	Lavigne EG, Buttigieg D, Steinschneider R, Burstein ES. Pimavanserin promotes trophic factor release and protects cultured primary dopaminergic neurons exposed to MPP+in a GDNF-dependent manner. ACS Chem Neurosci, 2021, 12: 2088- 2098. doi: 10.1021/acschemneuro.0c00751
45	Tsitsipa E, Rogers J, Casalotti S, Belessiotis-Richards C, Zubko O, Weil RS, Howard R, Bisby JA, Reeves S. Selective 5HT3 antagonists and sensory processing: a systematic review. Neuropsychopharmacology, 2022, 47: 880- 890. doi: 10.1038/s41386-021-01255-4

[1]	魏俊吉, 常健博. 深入基层医院普及神经外科重症管理理念[J]. 中国现代神经疾病杂志, 2024, 24(6): 403-406.
[2]	李海峰. 在进入靶向治疗的时代激素仍然是重症肌无力治疗的基础[J]. 中国现代神经疾病杂志, 2024, 24(5): 295-307.
[3]	许鸿嘉, 舒崖清, 王蘋, 李蕃, 许顺良, 邱伟, 马晓宇. 抗水通道蛋白4抗体阳性视神经脊髓炎谱系疾病诊断与治疗进展[J]. 中国现代神经疾病杂志, 2024, 24(5): 308-314.
[4]	黄瑀, 廖金池, 舒崖清. 抗N-甲基-D-天冬氨酸受体脑炎睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2024, 24(5): 315-319.
[5]	刘彩云, 金涛. 树突状细胞在多发性硬化免疫治疗中的应用[J]. 中国现代神经疾病杂志, 2024, 24(5): 320-330.
[6]	王军成, 赵岳阳, 杨强, 蒯涛, 潘亚文. HMGB1基因调控胶质瘤恶性生物学行为研究进展[J]. 中国现代神经疾病杂志, 2024, 24(5): 391-397.
[7]	王佳伟, 刘磊, 冯国栋. 开启感染神经病学学科建设新纪元[J]. 中国现代神经疾病杂志, 2024, 24(4): 199-202.
[8]	王晓娟, 蒋玙舒, 秦灵芝, 张弥兰, 王佳伟, 李玮. 人类伪狂犬病毒感染性脑炎的诊断与治疗[J]. 中国现代神经疾病杂志, 2024, 24(4): 203-207.
[9]	刘玉晓, 姚勇, 张毅. 经蝶窦鞍区病变手术后迟发性低钠血症[J]. 中国现代神经疾病杂志, 2024, 24(4): 280-284.
[10]	王含, 王一淳, 张哲. 应重视自主神经功能障碍在中枢性α-突触核蛋白病诊断与预后预测中的作用[J]. 中国现代神经疾病杂志, 2024, 24(3): 113-119.
[11]	王刚, 李彬寅, 任汝静, 肖金雯, 陈生弟, 陈晓春. 关于抗Aβ单克隆抗体的临床应用建议（2024版）[J]. 中国现代神经疾病杂志, 2024, 24(3): 120-126.
[12]	姜雨菡, 周梦溪, 陈伟. 前庭诱发肌源性电位在帕金森病诊断中的应用[J]. 中国现代神经疾病杂志, 2024, 24(3): 127-130.
[13]	徐滢, 桂雅星. 脂质代谢异常对帕金森病进程的影响及临床意义[J]. 中国现代神经疾病杂志, 2024, 24(3): 131-138.
[14]	叶诗怡, 张克忠. 帕金森病构音障碍[J]. 中国现代神经疾病杂志, 2024, 24(3): 139-145.
[15]	毕怡青, 吴凤娟, 朱玉港, 刘艺鸣. 帕金森病躯干前屈症发病机制及治疗[J]. 中国现代神经疾病杂志, 2024, 24(3): 146-150.

选择文件类型/文献管理软件名称

选择包含的内容

2 5-羟色胺与帕金森病非运动症状研究进展

Advance on association between 5-hydroxytryptamine and non-motor symptoms in Parkinson's disease

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 5-羟色胺与帕金森病非运动症状研究进展

Advance on association between 5-hydroxytryptamine and non-motor symptoms in Parkinson's disease

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献 45

相关文章 15

编辑推荐

Metrics

本文评价